ALKS vs AXSM
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders.
Side-by-side fundamentals
| Metric | ALKS | AXSM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $44.11 | $159.58 | |
| Market cap | $7.4B | $8.4B | |
| P/E as of 2026-10-20 | 116.08 | n/a | |
| Net margin FY2025, SEC XBRL | +16.4% | -28.7% | ALKS higher |
| Operating margin FY2025, SEC XBRL | +17.2% | -26.1% | ALKS higher |
| ROE FY2025, SEC XBRL | +13.3% | -207.5% | ALKS higher |
| ROA FY2025, SEC XBRL | +9.7% | -26.6% | ALKS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.83 | 2.26 | ALKS lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -5.3% | +65.5% | AXSM higher |
| Revenue CAGR (3y) SEC XBRL | +9.9% | +133.7% | AXSM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.69 | 0.66 | |
| 1-year return as of 2026-10-20 close | +42.4% | +21.3% | ALKS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.